KNSA - Company ID 0001730430
Kiniksa Pharmaceuticals, Ltd. trades as KNSA and has a market capitalization of $3.75 B, making it the #1663 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $677.56M, up 60.1% from the prior year and net income of $59.01M. This page tracks Kiniksa Pharmaceuticals, Ltd. through 733 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-05-29
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 4 fiscal years Kiniksa Pharmaceuticals, Ltd.'s revenue grew from $38.54M to $677.56M, a compound annual growth rate of 104.8%. Net profit margin expanded from -409.7% to 8.7% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-26 |
| SCHEDULE 13D/A | - | 2026-05-26 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| Insider trade | 4 | 2026-05-05 |
| Insider sale notice | 144 | 2026-05-01 |
| Major company event | 8-K | 2026-05-01 |
| Insider trade | 4 | 2026-05-01 |
| Insider trade | 4 | 2026-04-30 |
– ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth –
A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com . Individuals interested in participating in the call via telephone may register here . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
– Educational campaign to raise awareness of recurrent pericarditis and to empower patients to discuss ARCALYST with their healthcare provider –
Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference
– ARCALYST ® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –
The largest companies sharing Kiniksa Pharmaceuticals, Ltd.'s SEC industry classification (pharmaceutical preparations).
Kiniksa Pharmaceuticals, Ltd. (KNSA) has a market capitalization of $3.75 B as of 2026-05-29, ranking #1663 among US-listed companies.
Kiniksa Pharmaceuticals, Ltd. reported revenue of $677.56M for fiscal year 2025, an increase of 60.1% year over year.
Yes. Kiniksa Pharmaceuticals, Ltd. reported net income of $59.01M in its latest fiscal year.